PLA2G12B

Across TCGA pan-cancer cohorts, PLA2G12B Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PLA2G12B data layer compared with 20 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PLA2G12B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PLA2G12B expression acts as an unfavorable survival marker.

HNSC, CESC, and SKCM are the cancer types where PLA2G12B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	III,IV	0.174	0.726	.003	21	view →
CESC	DFS	Median	II,III,IV	0.184	0.705	.036	14	view →
SKCM	DFS	Median	III,IV	0.157	0.653	.020	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PLA2G12B–HNSC (OS)

Open the HNSC breakdown →